Seladelpar

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Primary biliary cholangitis: current insights and novel therapies.

Primary biliary cholangitis: current insights and novel therapies.

Journal: Expert review of clinical immunology

Published: May 10, 2026

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.

Journal: Journal of comparative effectiveness research

Published: April 17, 2026

The emerging role of PPARs in primary biliary cholangitis.

The emerging role of PPARs in primary biliary cholangitis.

Journal: Trends in molecular medicine

Published: February 27, 2026

Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With PBC Treated With Seladelpar: Results From the ASSURE Study Up to 30 Months.

Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With PBC Treated With Seladelpar: Results From the ASSURE Study Up to 30 Months.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With PBC Treated Up to 48 Months in the Ongoing, Open-Label ASSURE Study.

Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With PBC Treated Up to 48 Months in the Ongoing, Open-Label ASSURE Study.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With PBC.

36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With PBC.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model.

Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 06, 2026

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.

Journal: Annals of gastroenterology

Published: December 24, 2025

Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis.

Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis.

Journal: Pharmacological research

Published: December 18, 2025

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

New and emerging treatments for PBC-related pruritus.

New and emerging treatments for PBC-related pruritus.

Journal: Drugs in context

Published: December 09, 2025

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids.

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids.

Journal: International journal of molecular sciences

Published: November 12, 2025

Showing 1-12 of 99

Last Updated: 06/30/2026